(Q40640597)

22 September 2017

title

Prognostic impact of Cyfra21-1 and other serum markers in completely resected non-small cell lung cancer (English)

1 reference

22 September 2017

2

1 reference

22 September 2017

Niels Reinmuth

1

1 reference

22 September 2017

Michael Semik

3

1 reference

22 September 2017

Wolf-Peter Kunze

4

1 reference

22 September 2017

Richard Achatzy

5

1 reference

22 September 2017

Hans H Scheld

6

1 reference

22 September 2017

Petra Broermann

7

1 reference

22 September 2017

Wolfgang E Berdel

8

1 reference

22 September 2017

Hans N Macha

9

1 reference

22 September 2017

Michael Thomas

10

1 reference

22 September 2017

publication date

1 June 2002

1 reference

22 September 2017

1 reference

22 September 2017

volume

36

1 reference

22 September 2017

issue

3

1 reference

22 September 2017

page(s)

265-270

1 reference

Study of prognostic predictors for non-small cell lung cancer.

22 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900009-0

7 January 2021

Revisions in the International System for Staging Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900009-0

7 January 2021

Molecular and pathologic markers in stage I non-small-cell carcinoma of the lung

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900009-0

7 January 2021

Evaluation of a new tumour marker in patients with non-small-cell lung cancer: Cyfra 21.1.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900009-0

7 January 2021

Prediction of survival and recurrence by serum and cytosolic levels of CEA, CA125 and SCC antigens in resectable non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900009-0

7 January 2021

Clinical significance of a multiple biomarker assay in patients with lung cancer. A study with logistic regression analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900009-0

7 January 2021

Preoperative carcinoembryonic antigen level as a prognostic indicator in resected primary lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900009-0

7 January 2021

Neuron-specific enolase in the diagnosis and therapy monitoring of lung cancer: a comparison with CEA, TPA, ferritin and calcitonin

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900009-0

7 January 2021

Serum neuron-specific enolase: a marker for disease extent and response to therapy of small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900009-0

7 January 2021

Cyfra 21-1, neuron specific enolase and prognosis of non-small cell lung cancer: prospective study in 621 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900009-0

7 January 2021

Radioimmunoassay for tumor antigen of human cervical squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900009-0

7 January 2021

The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900009-0

7 January 2021

CYFRA 21-1. A new marker in lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900009-0

7 January 2021

Evaluation of tissue polypeptide specific antigen, CYFRA 21-1, and carcinoembryonic antigen in nonsmall cell lung carcinoma: does the combined use of cytokeratin markers give any additional information?

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900009-0

7 January 2021

Cytokeratins as serum markers in lung cancer: a comparison of CYFRA 21-1 and TPS

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900009-0

7 January 2021

The clinical value of Cyfra 21-1 estimation for lung cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900009-0

7 January 2021

Diagnostic and Prognostic Value of Cyfra 21-1 Compared with Other Tumour Markers in Patients with Non-small Cell Lung Cancer: A Prospective Study of 116 Patients

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900009-0

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900009-0

7 January 2021

Different cutoff values of Cyfra 21-1 for cavitary and noncavitary lung cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900009-0

7 January 2021

Diagnostic and prognostic value of the new tumour marker CYFRA 21-1 in patients with squamous cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900009-0

7 January 2021

Determinants of long term survival after surgery for cancer of the lung: A population-based study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900009-0

7 January 2021

Prognostic factors in lung cancer: tables and comments

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900009-0

7 January 2021

The role of chemotherapy in early-stage (stage I and II) resectable non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900009-0

7 January 2021

A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900009-0

7 January 2021

Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: a 7-year assessment of a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900009-0

7 January 2021

A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900009-0

7 January 2021

Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900009-0

7 January 2021

Ploidy, expression of erbB1, erbB2, P53 and amplification of erbB1, erbB2 and erbB3 in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900009-0

7 January 2021

10.1016/S0169-5002(02)00009-0

Identifiers

DOI

1 reference

22 September 2017

1 reference